311 related articles for article (PubMed ID: 8609429)
21. Stimulation of human T cells by streptococcal "superantigen" erythrogenic toxins (scarlet fever toxins).
Braun MA; Gerlach D; Hartwig UF; Ozegowski JH; Romagné F; Carrel S; Köhler W; Fleischer B
J Immunol; 1993 Mar; 150(6):2457-66. PubMed ID: 8450222
[TBL] [Abstract][Full Text] [Related]
22. Isolation and characterization of a novel streptococcal superantigen.
Mollick JA; Miller GG; Musser JM; Cook RG; Rich RR
Trans Assoc Am Physicians; 1992; 105():110-22. PubMed ID: 1308988
[TBL] [Abstract][Full Text] [Related]
23. [Invasive streptococcal infections].
Kosina P; Plísek S; Dostál V; Morávková M; Cermák P; Preis J; Lukes A; Kracmarová R; Krausová J
Klin Mikrobiol Infekc Lek; 2007 Dec; 13(6):220-4. PubMed ID: 18320500
[TBL] [Abstract][Full Text] [Related]
24. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation.
MacMillan HF; Lee T; Issekutz AC
Clin Immunol; 2009 Aug; 132(2):222-33. PubMed ID: 19447680
[TBL] [Abstract][Full Text] [Related]
25. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome.
Schrage B; Duan G; Yang LP; Fraser JD; Proft T
Clin Infect Dis; 2006 Sep; 43(6):743-6. PubMed ID: 16912949
[TBL] [Abstract][Full Text] [Related]
26. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.
Arad G; Levy R; Hillman D; Kaempfer R
Nat Med; 2000 Apr; 6(4):414-21. PubMed ID: 10742148
[TBL] [Abstract][Full Text] [Related]
27. Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project.
Watanabe-Ohnishi R; Low DE; McGeer A; Stevens DL; Schlievert PM; Newton D; Schwartz B; Kreiswirth B; Kotb M
J Infect Dis; 1995 Jan; 171(1):74-84. PubMed ID: 7798684
[TBL] [Abstract][Full Text] [Related]
28. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004.
O'Loughlin RE; Roberson A; Cieslak PR; Lynfield R; Gershman K; Craig A; Albanese BA; Farley MM; Barrett NL; Spina NL; Beall B; Harrison LH; Reingold A; Van Beneden C;
Clin Infect Dis; 2007 Oct; 45(7):853-62. PubMed ID: 17806049
[TBL] [Abstract][Full Text] [Related]
29. Lethal shock induced by streptococcal pyrogenic exotoxin A in mice transgenic for human leukocyte antigen-DQ8 and human CD4 receptors: implications for development of vaccines and therapeutics.
Welcher BC; Carra JH; DaSilva L; Hanson J; David CS; Aman MJ; Bavari S
J Infect Dis; 2002 Aug; 186(4):501-10. PubMed ID: 12195377
[TBL] [Abstract][Full Text] [Related]
30. Comparative study of the effects of betamethasone butyrate propionate, vitamin D3 derivatives, and cyclosporine on human lymphocyte-proliferation stimulated with a hemolytic streptococci-derived superantigen.
Arai K; Uchiyama T; Okubo Y; Tsuboi R; Oka K; Hirano T
Eur J Pharmacol; 2007 Oct; 571(2-3):222-30. PubMed ID: 17628528
[TBL] [Abstract][Full Text] [Related]
31. Soluble M1 protein of Streptococcus pyogenes triggers potent T cell activation.
Påhlman LI; Olin AI; Darenberg J; Mörgelin M; Kotb M; Herwald H; Norrby-Teglund A
Cell Microbiol; 2008 Feb; 10(2):404-14. PubMed ID: 17900297
[TBL] [Abstract][Full Text] [Related]
32. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
Darenberg J; Ihendyane N; Sjölin J; Aufwerber E; Haidl S; Follin P; Andersson J; Norrby-Teglund A;
Clin Infect Dis; 2003 Aug; 37(3):333-40. PubMed ID: 12884156
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.
Linnér A; Darenberg J; Sjölin J; Henriques-Normark B; Norrby-Teglund A
Clin Infect Dis; 2014 Sep; 59(6):851-7. PubMed ID: 24928291
[TBL] [Abstract][Full Text] [Related]
34. Diffuse venous thromboemboli associated with IVIg therapy in the treatment of streptococcal toxic shock syndrome: case report and review.
Geller JL; Hackner D
Ann Hematol; 2005 Sep; 84(9):601-4. PubMed ID: 15815906
[TBL] [Abstract][Full Text] [Related]
35. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection.
Norrby-Teglund A; Chatellier S; Low DE; McGeer A; Green K; Kotb M
Eur J Immunol; 2000 Nov; 30(11):3247-55. PubMed ID: 11093140
[TBL] [Abstract][Full Text] [Related]
36. Pyrogenicity and cytokine-inducing properties of Streptococcus pyogenes superantigens: comparative study of streptococcal mitogenic exotoxin Z and pyrogenic exotoxin A.
Müller-Alouf H; Proft T; Zollner TM; Gerlach D; Champagne E; Desreumaux P; Fitting C; Geoffroy-Fauvet C; Alouf JE; Cavaillon JM
Infect Immun; 2001 Jun; 69(6):4141-5. PubMed ID: 11349089
[TBL] [Abstract][Full Text] [Related]
37. Increased surface toll-like receptor 2 expression in superantigen shock.
Hopkins PA; Pridmore AC; Ellmerich S; Fraser JD; Russell HH; Read RC; Sriskandan S
Crit Care Med; 2008 Apr; 36(4):1267-76. PubMed ID: 18379254
[TBL] [Abstract][Full Text] [Related]
38. Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease.
Akesson P; Rasmussen M; Mascini E; von Pawel-Rammingen U; Janulczyk R; Collin M; Olsen A; Mattsson E; Olsson ML; Bjorck L; Christensson B
J Infect Dis; 2004 Mar; 189(5):797-804. PubMed ID: 14976595
[TBL] [Abstract][Full Text] [Related]
39. Defense against biologic warfare with superantigen toxins.
Kaempfer R; Arad G; Levy R; Hillman D
Isr Med Assoc J; 2002 Jul; 4(7):520-3. PubMed ID: 12120463
[TBL] [Abstract][Full Text] [Related]
40. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome.
Eriksson BK; Andersson J; Holm SE; Norgren M
J Infect Dis; 1999 Aug; 180(2):410-8. PubMed ID: 10395857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
